Vtv Therapeutics Inc Quick Ratio (VTVT) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Vtv Therapeutics Inc   (NASDAQ: VTVT)

Vtv Therapeutics Inc 's Quick Ratio

VTVT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 10.99 above Vtv Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 88 other companies have achieved higher Quick Ratio than Vtv Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 230 to 384.

Explain Quick Ratio?
How much Cash & cash equivalents VTVT´s has?
What are VTVT´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VTVT/financial-strength
https://api.csimarket.com/api/v1/companies/VTVT/fundamentals
https://api.csimarket.com/api/v1/companies/VTVT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
VTVT Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -30.67 %
Y / Y Cash & cash equivalent Change -21.66 %
Quick Ratio MRQ 10.99
VTVT's Total Ranking # 384
Seq. Current Liabilities Change 0.1 %
Seq. Cash & cash equivalent Change -10.94 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 89
Healthcare Sector # 131
Overall Market # 384


Quick Ratio Statistics
High Average Low
17.45 3.84 0.04
(Sep 30 2015)   (Jun 30 2015)




Financial Statements
Vtv Therapeutics Inc 's Current Liabilities $ 7 Millions Visit VTVT's Balance sheet
Vtv Therapeutics Inc 's Cash & cash equivalent $ 77 Millions Visit VTVT's Balance sheet
Source of VTVT's Sales Visit VTVT's Sales by Geography


Cumulative Vtv Therapeutics Inc 's Quick Ratio

VTVT's Quick Ratio for the trailling 12 Months

VTVT Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 11.44 %
Y / Y Cash & cash equivalent TTM Growth 82.42 %
Quick Ratio TTM 12.73
Total Ranking TTM # 3147
Seq. Current Liabilities TTM Growth -10.13 %
Seq. Cash & cash equivalent TTM Growth -5.73 %


On the trailing twelve months basis Current Liabilities decreased faster than Vtv Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Vtv Therapeutics Inc 's Quick Ratio to 12.73, above VTVT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Vtv Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2409 to 3147.

Explain Quick Ratio?
How much Cash & cash equivalents VTVT´s has?
What are VTVT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 411
Healthcare Sector # 829
Within the Market # 3147


trailing twelve months Quick Ratio Statistics
High Average Low
12.12 3.13 0.13
(Jun 30 2026)   (Mar 31 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Pasithea Therapeutics Corp   29.91 $ 82.419  Millions$ 2.756  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Silo Pharma Inc  22.91 $ 8.051  Millions$ 0.351  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Silence Therapeutics Plc  22.00 $ 247.659  Millions$ 11.259  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Relmada Therapeutics Inc  19.30 $ 202.123  Millions$ 10.474  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Equillium Inc   18.92 $ 53.322  Millions$ 2.819  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Benitec Biopharma Inc   18.38 $ 176.368  Millions$ 9.594  Millions
Alto Neuroscience Inc   17.90 $ 319.344  Millions$ 17.836  Millions
Monopar Therapeutics Inc   17.65 $ 52.634  Millions$ 2.982  Millions
Upstream Bio Inc   17.34 $ 207.365  Millions$ 11.960  Millions
Siga Technologies Inc  17.27 $ 116.380  Millions$ 6.738  Millions
Arrivent Biopharma inc   16.86 $ 393.691  Millions$ 23.357  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Whitehawk Therapeutics Inc   16.25 $ 169.672  Millions$ 10.441  Millions
Palvella Therapeutics Inc   15.85 $ 236.680  Millions$ 14.928  Millions
Jade Biosciences Inc   15.70 $ 475.706  Millions$ 30.293  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions

Date modified: 2026-11-06T06:13:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.